-- （新增伍德赛德能源公司评论） 据路透社周四报道，总部位于澳大利亚的伍德赛德能源公司（WDS）正努力为其计划在路易斯安那州建设的液化天然气（LNG）出口设施寻找买家。 报道称，主要障碍在于该公司坚持收取高于美国市场平均水平的液化费。液化费是指在天然气基础价格基础上增加的加工运输成本。 报道指出，尽管由于劳动力短缺和建设成本上升，全球液化费都在上涨，但伍德赛德能源公司高昂的定价可能已经设定了美国液化天然气出口价格的上限。 报道称，伍德赛德能源公司最初寻求的液化费超过每百万英热单位（BTU）2.80美元，远高于美国通常的2.40至2.50美元的价格区间。 相比之下，行业领头羊切尼尔能源公司（LNG）的收费约为每百万英热单位2.60美元，而Venture Global公司（VG）的收费则较低，约为每百万英热单位2.30美元。 伍德赛德能源公司发言人在发给的电子邮件中表示：“正如公开宣布的那样，路易斯安那液化天然气项目约1050万吨/年的产能已达成协议。这其中包括伍德赛德能源公司计划将约800万吨/年的产能纳入其全球液化天然气投资组合，与尤尼珀公司签订的100万吨/年的FOB液化天然气销售和购买协议，以及与威廉姆斯公司签订的约150万吨/年的股权承购协议。” 该发言人还表示：“伍德赛德能源公司对路易斯安那液化天然气项目的合同签订势头充满信心，并将继续通过正常的市场披露渠道提供最新信息。” （市场动态新闻来源于与全球市场专业人士的对话。这些信息被认为是来自可靠来源，但可能包含传闻和猜测。准确性无法保证。）
Related Articles
Research
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
$INCY
Australia
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
$GSK
International
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.